Another stock from the Zacks Medical - Biomedical and Genetics industry, Alnylam Pharmaceuticals (ALNY) , is soon expected to post loss of $0.71 per share for the quarter ended June 2024. This estimate indicates a yearover-year change of +67.9%. Revenues for the quarter are expected to be $452.73 million, up 42% from the year-ago quarter. The market expects CRISPR Therapeutics AG (CRSP) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. ...